Ionis has gained US Food and Drug Administration approval for Tryngolza, making it the first treatment in the US for the rare metabolic disease familial chylomicronemia syndrome (FCS), and giving it a head start over rival Arrowhead.
Ionis To Get Head Start On Arrowhead With Tryngolza Launch
The antisense oligonucleotide specialist is ready to launch its rare disease therapy Tryngolza but could face competition from a more potent rival by mid-2025.
